tofacitinib / Generic mfg. - LARVOL DELTA

TARA: A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs (clinicaltrials.gov) - P3 | N=459 | Completed | Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Aug 2026

Head-to-Head • Monotherapy • Trial completion • Trial completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Tofacitinib does not affect platelet function or coagulation in patients with ulcerative colitis. (PubMed, Front Immunol) - "Regarding thrombus dynamics, a significant difference was observed only in the INTEM assay when comparing the tofacitinib and anti-TNF groups, showing longer clot formation times in tofacitinib-treated patients; however, neither group differed from HC. In this study, tofacitinib treatment was not associated with increased platelet aggregation, platelet activation, or enhanced coagulation in patients with UC."

Journal • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatoid Arthritis • Rheumatology • Thrombosis • Ulcerative Colitis • CD63 • SELP

Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study (clinicaltrials.gov) - P2 | N=10 | Active, not recruiting | Sponsor: Hexsel Dermatology Clinic | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Mar 2027 ➔ Sep 2027 | Initiation date: Mar 2026 ➔ Sep 2026 | Trial primary completion date: Jan 2027 ➔ Apr 2027

Enrollment closed • Trial completion date • Trial initiation date • Trial primary completion date • Dermatology • Immunology • Psoriasis

Comparative Effectiveness of Janus Kinase Inhibitors Versus Vedolizumab for Chronic Pouchitis (ACG 2026) - "Adult patients, >= 18 years, with pouchitis who received either a JAK inhibitor (tofacitinib or upadacitinib) or vedolizumab were identified. After 1:1 propensity score matching, 336 patients remained in each cohort. Baseline demographics and disease characteristics were well balanced after matching. The mean age was 44 years in both groups; 45% were female; 83% were White.At 1 year, 156 patients (46.4%) in the JAKi cohort and 173 patients (51.5%) in the vedolizumab cohort experienced relapse (aHR 0.94, 95% CI 0.76–1.17, p=0.56)."

HEOR • Gastrointestinal Disorder • Inflammation

Advanced Therapy Exposure Is Associated With Increased Disease-Related Surgery but Not Cancer Risk in PSC-IBD: A Real-World Analysis (ACG 2026) - "Patients receiving advanced IBD therapies (anti-TNF agents, vedolizumab, ustekinumab, tofacitinib, upadacitinib, risankizumab, mirikizumab, or guselkumab) were compared with PSC-IBD patients without advanced therapy exposure. Among 4,116 eligible PSC-IBD patients, 723 advanced-therapy patients were matched to 723 non-advanced therapy patients. Advanced therapy exposure was associated with a significantly increased risk of IBD-related surgery (12.7% vs 5.3%; RR 2.42, 95% CI 1.68â3.48; p< 0.001) and higher corticosteroid utilization (59.3% vs 47.9%; RR 1.24, 95% CI 1.13â1.37; p< 0.001). Advanced therapy patients also demonstrated shorter surgery-free survival (HR 2.43, 95% CI 1.67â3.55; p< 0.001)."

Clinical • Metastases • Real-world • Real-world evidence • Surgery • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Crohn's disease • Gallbladder Cancer • Gastroenterology • Gastrointestinal Disorder • Hepatocellular Cancer • Hepatology • Immunology • Inflammatory Bowel Disease • Oncology • Primary Sclerosing Cholangitis • Solid Tumor • Ulcerative Colitis

Safety and Effectiveness of Janus Kinase Inhibitors Versus Infliximab in Older Adults With Inflammatory Bowel Disease (ACG 2026) - " This single-center retrospective cohort study included adults with IBD who were started on either IFX or JAKi (upadacitinib or tofacitinib) at ageâ¥55 years old. A total of 386 patients were included in the study (JAKi n=148, mean age 64 years vs. IFX n=238, median age 62, p=0.004, Table). The JAKi group had higher rates of cardiovascular comorbidities (hypertension, hyperlipidemia, atrial fibrillation, stroke, peripheral vascular disease, pulmonary embolism, angina, or heart failure) at the time of starting medication (75% JAKi vs 58% IFX p=0.001)."

Clinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hypertension • Immunology • Inflammation • Inflammatory Bowel Disease • Peripheral Arterial Disease • Pulmonary Embolism • Respiratory Diseases

Biologic Sequencing After First-Line Anti-TNF Failure in IBD: An Umbrella Review of Meta-Analyses on Second- and Third-Line Options, Comparative Effectiveness, and Treat-to-Target Outcomes (ACG 2026) - "In biologic-experienced UC, upadacitinib ranked highest for maintenance (RR 7.04; 95% CI 2.51-19.79), while tofacitinib and ustekinumab led induction rankings. Fourteen MAs and NMAs met inclusion criteria (10 high-quality, AMSTAR-2 â¥12/16). In anti-TNF-experienced CD, ustekinumab demonstrated superior maintenance remission (OR 1.86; 95% CI 1.23-2.82; I²=80%) and treatment persistence (OR 2.37; 95% CI 1.56-3.62; I²=0%) versus vedolizumab. SUCRA rankings placed ustekinumab (86.19%) and risankizumab (62.56%) highest for induction in TNF-experienced CD."

Clinical • HEOR • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Drug-Induced Pancreatitis Across UC Therapeutics: A Real-World Pharmacovigilance Study (ACG 2026) - " FAERS was queried for reports of pancreatitis associated with UC treatments including immunomodulators (azathioprine, mercaptopurine, methotrexate, tacrolimus), 5-aminosalicylates (mesalamine, balsalazide, olsalazine, sulfasalazine), anti-TNF agents (adalimumab, infliximab, golimumab, certolizumab pegol), integrin inhibitors (vedolizumab, natalizumab), IL-12/23 inhibitors (ustekinumab, risankizumab, guselkumab), JAK inhibitors (tofacitinib, upadacitinib), and S1P modulators (ozanimod, etrasimod). 83,046 reports with 612 pancreatitis cases were analyzed. Significantly elevated risk was observed with azathioprine (ROR 4.38, 95% CI 3.56-5.38), mesalamine (ROR 2.32, 95% CI 1.87-2.89), and infliximab (ROR 1.47, 95% CI 1.21-1.80; all p< 0.0001). Reduced risk was identified with adalimumab (ROR 0.60, 95% CI 0.49-0.74), vedolizumab (ROR 0.69, 95% CI 0.51-0.93), and ustekinumab (ROR 0.13, 95% CI 0.02-0.94)."

Adverse events • Clinical • Real-world • Real-world evidence • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pancreatitis • Ulcerative Colitis • IL12A • ROR1

Cutaneous Kaposi Sarcoma in a Patient With Ulcerative Colitis: Progression on Infliximab and Regression After Withdrawal (ACG 2026) - "If colitis relapses, non-TNF options require caution, as KS has also been reported with vedolizumab, tofacitinib, ozanimod, and upadacitinib. (D) Marked regression ~6 months after infliximab withdrawal, with residual hyperpigmented macules and scarring. (consented)"

Clinical • Dermatopathology • Epstein-Barr Virus Infections • Gastroenterology • Gastrointestinal Disorder • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammatory Bowel Disease • Kaposi Sarcoma • Sarcoma • Solid Tumor • Ulcerative Colitis • CD34 • TNFA

Herpes Zoster Infection as an Adverse Reaction to Treatments for Ulcerative Colitis: A Review of Reports to the FDA Adverse Events Reporting System (FAERS) (ACG 2026) - "Reports of ADRs of all FDA approved UC therapies including mesalamine, sulfasalazine, balsalazide, olsalazine, methotrexate, azathioprine, 6-mercaptopurine, infliximab, adalimumab, certolizumab, golimumab, vedolizumab, ustekinumab, mirikizumab, risankizumab, guselkumab, ozanimod, etrasimod, tofacitinib, and upadacitinib along with combination infliximab with methotrexate, infliximab with azathioprine, adalimumab with azathioprine, and golimumab with azathioprine were reviewed. Table 1 displays the total FAERS reports of ADRs and reported HZ infection in patients treated for UC. The JAK inhibitor tofacitinib showed increased risk of HZ with 58 total reports (ROR 2.79). In addition, methotrexate (ROR 1.83), azathioprine (ROR 1.74), 6-mercaptopurine (ROR 2.4), infliximab (ROR 2.49), and combination therapies of infliximab with methotrexate (ROR 2.61) and infliximab with azathioprine (ROR 2.91) demonstrated increased risk."

Adverse events • Review • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster • ROR1

Prevalence and Outcomes of Hormone Therapy Use Among Menopausal Women With Inflammatory Bowel Disease (ACG 2026) - "However, patients with CD prescribed systemic HT had higher oral prednisone use, while osteoporosis/fracture outcomes were lower among patients receiving systemic HT. Figure: 1-Systemic non-transdermal HRT included oral estradiol, conjugated estrogens, esterified estrogens, synthetic conjugated estrogens A and B, oral progesterone, oral medroxyprogesterone, conjugated estrogens/bazedoxifene (Duavee), estradiol acetate vaginal ring (Femring), and norethindrone acetate/ethinyl estradiol (Femhrt). 2-Systemic transdermal HRT included estradiol/norethindrone acetate transdermal patch (CombiPatch), estradiol/levonorgestrel transdermal patch (Climara Pro), estradiol transdermal patches (Alora, Climara, Dotti, Estraderm, Lyllana, Minivelle, Vivelle-Dot), estradiol transdermal gel (EstroGel, Divigel), and estradiol transdermal spray (Evamist). 3-Local estrogen therapy included low-dose vaginal estradiol formulations (Estring, Imvexxy, Vagifem, and Yuvafem) and vaginal conjugated..."

Clinical • Cardiovascular • Coronary Artery Disease • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Pulmonary Embolism • Respiratory Diseases • Ulcerative Colitis

Sustained Clinical and Endoscopic Improvements With up to 3 Years of Risankizumab Maintenance Treatment in Patients With Moderate to Severe Ulcerative Colitis Regardless of the Number of Prior Advanced Therapy Exposures (ACG 2026) - "AT included approved biologics for UC (infliximab, adalimumab, golimumab, ustekinumab, and/or vedolizumab), approved Janus kinase inhibitors for UC (tofacitinib, filgotinib, upadacitinib), and/or ozanimod. At induction baseline, among the 1003 pts included in the AO analysis, 29.4% (N=295) were AT-naïve; 29.4% (N=295) and 41.2% (N=418) had previously experienced 1 and >1 AT, respectively. Among the RZB180 and RZB360 groups, rates of CR (per AMS or PAMS) generally remained stable at OLE W0 and 96, regardless of the number of prior AT exposures, per AO analysis. Rates of endoscopic improvement and remission were sustained, regardless of the number of prior AT exposures, per AO analysis."

Clinical • Metastases • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Risk of Herpes Zoster in Patients With Inflammatory Bowel Disease Treated With Janus Kinase Inhibitors Compared With Anti-TNF Therapy: A Retrospective Cohort Study (ACG 2026) - "2 Advanced therapy was defined infliximab, adalimumab, certolizumab pegol, golimumab, vedolizumab, ustekinumab, tofacitinib, upadacitinib, risankizumab, etrasimod, ozanimod, guselkumab, and mirikizumab. Among 8,293 patients with IBD, 3,164 received JAKi and 5,129 received anti-TNF therapy (Table 1). JAKi-treated patients had higher HZ incidence rates than anti-TNF patients (32.81 vs. 14.58 per 1,000 person-years; p< 0.001)."

Retrospective data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster

Comparative Efficacy and Safety of Etrasimod Versus Ozanimod, JAK Inhibitors, and Placebo in Adults With Moderate to Severe Ulcerative Colitis (ACG 2026) - "Regarding safety, filgotinib 100 mg was the only treatment significantly reducing any-TEAE risk versus placebo (OR 0.82; 95% CrI 0.68-0.98), while ozanimod 1 mg was the only treatment significantly increasing TEAE risk (OR 1.71; 95% CrI 1.22-2.40). Up to 28 RCTs enrolling 8,377 participants were included. For induction clinical remission (18 RCTs; N=6,562), upadacitinib 45 mg ranked highest (OR 9.92, 95% CrI 5.81-18.11; SUCRA 90%), followed by ozanimod 1 mg (OR 4.37; SUCRA 63%), tofacitinib 10 mg induction (OR 4.23; SUCRA 60%), and etrasimod 2 mg (OR 3.61; SUCRA 52%). For induction clinical response, upadacitinib 45 mg again ranked first (OR 7.84; SUCRA 94%), with etrasimod 2 mg (OR 3.01; SUCRA 59%) and tofacitinib 10 mg (OR 2.96; SUCRA 58%) performing comparably."

Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Real-World Cardiovascular Outcomes Following Janus Kinase and IL-23p19 Inhibitor Therapy in Inflammatory Bowel Disease (ACG 2026) - "Adults with Crohnâs disease or ulcerative colitis who initiated a JAK inhibitor (tofacitinib, upadacitinib, or filgotinib) or an IL-23p19 inhibitor (risankizumab, mirikizumab, or guselkumab) within three years of IBD diagnosis were identified. Before matching, 11,998 patients received JAK inhibitors and 13,239 received IL-23p19 inhibitors. After matching, 11,206 patients remained in each cohort with balanced baseline characteristics. Compared with IL-23p19 inhibitors, JAK inhibitor therapy was associated with a higher risk of all-cause mortality (0.6% vs 0.4%; RR 1.75, 95% CI 1.19â2.58; p=0.004), MACE (1.2% vs 0.9%; RR 1.33, 95% CI 1.03â1.73; p=0.029), MI (0.6% vs 0.4%; RR 1.51, 95% CI 1.02â2.24; p=0.038), and VTE (1.9% vs 1.5%; RR 1.27, 95% CI 1.04â1.56; p=0.019)."

Clinical • Real-world • Real-world evidence • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Immunology • Inflammation • Inflammatory Bowel Disease • Myocardial Infarction • Ulcerative Colitis • Venous Thromboembolism

Real-World Data on JAK Inhibitors in Patients With Inflammatory Bowel Disease and Concomitant Primary Sclerosing Cholangitis: Safety Profile, Effectiveness, and Drug Persistence (ACG 2026) - "We aimed to describe clinical safety outcomes, HPBârelated events, and therapy persistence in a cohort of patients with PSCâIBD treated with upadacitinib (UPA) or tofacitinib (TOFA). We included 40 patients (29 UPA, 11 TOFA). Median follow-up was 26.9 months (IQR 38.9); 67.5% had large-duct PSC. Thirty-seven (92.5%) had prior exposure to â¥1 advanced IBD therapy; 12 (30.0%) to â¥3."

Clinical • Real-world • Real-world evidence • Dyslipidemia • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatology • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Primary Sclerosing Cholangitis • Varicella Zoster

Risk of Diverticulitis in Rheumatoid Arthritis Patients Treated With IL-6 Inhibitors Versus JAK Inhibitors: A Real-World Propensity-Matched Study (ACG 2026) - "Two mutually exclusive cohorts were defined: IL-6 inhibitor users (tocilizumab, sarilumab, siltuximab) without JAK inhibitor exposure, and JAK inhibitor users (tofacitinib, baricitinib, upadacitinib, filgotinib) without IL-6 exposure...Outcomes were assessed at 5 years, 10 years, and all follow-up after 1:1 propensity score matching for age, sex, diabetes, obesity, tobacco use, prior diverticular disease, alcohol-related disorders, NSAID, glucocorticoid, and methotrexate use... After matching, 10,459 patients remained per cohort, well-balanced (all standardized differences < =0.04). At 5 years, diverticulitis occurred in 160 IL-6 patients (1.6%) versus 146 JAK patients (1.4%): RR 1.092 (95% CI 0.874-1.365), p=0.436; HR 1.196 (0.955-1.497). At 10 years, 192 (1.9%) versus 172 (1.7%): RR 1.113 (0.907-1.365), p=0.304; HR 1.182 (0.962-1.453)."

Clinical • Real-world • Real-world evidence • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Obesity • Rheumatoid Arthritis • Rheumatology

Acute Severe Ulcerative Colitis Complicated by Concurrent Clostridioides difficile and ESBL Klebsiella Infection: A Therapeutic Dilemma (ACG 2026) - "Given ongoing disease and concern for progression to colectomy, tofacitinib was discontinued and infliximab was initiated before completion of antimicrobial treatment. Our case highlights the importance of individualized, multidisciplinary decision-making in selecting the rescue therapy in ASUC with concomitant infections. Figure: Figure 1: Descending Colon on Initial Flexible Sigmoidoscopy Figure: Figure 2: Descending Colon on Follow Up Flexible Sigmoidoscopy"

Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Nephrology • Pneumonia • Ulcerative Colitis

Beyond the Bowel: Concurrent Pyoderma Gangrenosum and Primary Sclerosing Cholangitis in Ulcerative Colitis Successfully Managed With Tofacitinib in a Steroid-Intolerant Patient (ACG 2026) - "The patient was initiated on prednisolone 1 mg/kg/day, mesalamine 1.2 g three times daily, and ursodeoxycholic acid 300 mg twice daily, with initial clinical improvement. C. Five months after initiation of tofacitinib therapy Figure: MRCP image showing short-segment narrowing (green arrow) and dilatation (blue arrow) of both hepatic ducts and bilobar IHBRs, giving a beaded appearance in places."

Clinical • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Immunology • Inflammatory Bowel Disease • Ophthalmology • Primary Sclerosing Cholangitis • Pyoderma Gangrenosum • Retinal Disorders • Ulcerative Colitis

Ramsay Hunt Syndrome Following Vedolizumab Initiation in Refractory Ulcerative Colitis (ACG 2026) - "He was treated with intravenous methylprednisolone and valacyclovir followed by oral prednisone and valacyclovir at discharge. His UC had been refractory to multiple therapies including infliximab and a recent 3-year course of tofacitinib...Vedolizumab was discontinued, and he was transitioned to risankizumab-rzaa with improved UC control and weight gain...Figure: Figure 1. White-mucocutaneous lesions on the right side of the patientâs hard palate, consistent with Ramsay Hunt Syndrome."

Cardiovascular • CNS Disorders • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hematological Disorders • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Bowel Disease • Otorhinolaryngology • Ulcerative Colitis • Varicella Zoster

Comparative Real-World Effectiveness and Safety of Upadacitinib Versus Tofacitinib in Ulcerative Colitis: A Systematic Review and Meta-Analysis (ACG 2026) - "The final analysis included 14 real-world cohorts and database studies comprising over 3,500 patients with UC. Upadacitinib demonstrated significantly higher induction response and remission compared with tofacitinib (OR 1.99, 95% CI 1.41â2.79; I² = 34.8%). It also showed superior maintenance steroid-free clinical remission across five cohorts (OR 2.06, 95% CI 1.38â3.07; I² = 24.1%)."

Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Review • Acne Vulgaris • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Metabolic Disorders • Ulcerative Colitis

Number Needed to Harm Applying Hazard Ratios From Cardiovascular Risk Enriched Oral Surveillance to Patients With Moderate-To-Severe Inflammatory Bowel Disease: Real-World Evidence From a Large US Claims Database (ACG 2026) - "Introduction: In 2021, the FDA issued a boxed warning for oral Janus kinase inhibitors (JAKi) after safety signals identified from the ORAL Surveillance study of tofacitinib in patients (pts) with rheumatoid arthritis aged â¥50 years and â¥1 additional cardiovascular (CV) risk factor... A total of 35,537 pts with CD and 23,134 with UC were identified (Table). For CD, 39% of pts had very low CV risk, 46% low CV risk, 1% medium CV risk, and 14% high CV risk; a similar distribution was observed for UC (Figure A). Applying ORAL Surveillanceâs VTE and MACE HRs to IBD pts aged 18-34 years with no additional CV risk factor translated to one VTE in every 1,416 CD or 663 UC pts (Figure B), and one MACE in every 12,332 CD or 20,106 UC pts (Figure C)."

Claims database • Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatoid Arthritis • Skin Cancer • Solid Tumor • Ulcerative Colitis • Venous Thromboembolism

Early Experience With Etrasimod in Ulcerative Colitis Patients: A Claims Database Study in the United States (ACG 2026) - "(e)Advanced treatments: adalimumab, golimumab, infliximab, vedolizumab, ustekinumab, mirikizumab, risankizumab, guselkumab, tofacitinib, upadacitinib, and ozanimod. A total of 297 patients were included (mean age, 47.3 years [SD, 17.5]; 52.2% male), and 127 comprised the follow-up population. In the follow-up population, most patients were AT-naïve (67.7%), and 48.0% had used steroids within 24 weeks prior to index date (Table 1). Through week 24, median adherence was 89.8% (quartile 1: 53.9%; quartile 3: 98.8%), and 59.1% of patients had PDC â¥0.80."

Claims database • Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Fecal Microbiota Transplantation in Refractory Immune Checkpoint Inhibitor-Induced Colitis (ACG 2026) - "Current National Comprehensive Cancer Network (NCCN) guidelines reserve FMT for patients who have failed initial corticosteroids, biologics including infliximab or vedolizumab, and additional agents such as tofacitinib or ustekinumab, or in whom such agents are contraindicated. Case Description/ A 70-year-old woman with metastatic melanoma was initiated on pembrolizumab 200 mg every 3 weeks...Her diarrhea remained refractory despite four tapering courses of prednisone and three doses of vedolizumab...Cholestyramine was briefly used for transient soft stool but discontinued due to constipation...Unlike traditional donor-derived FMT sourced from stool biorepositories, fecal microbiota, live-jslm offers a standardized and commercially available formulation that simplifies procurement and administration...While recent NCCN guidelines position FMT as salvage therapy, emerging data suggest that a single dose of FMT may induce steroid-free remission in a significant proportion..."

Checkpoint inhibition • Constipation • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Melanoma • Oncology • Solid Tumor • Transplantation

Real-World Effectiveness of Biologics and Small Molecules in Steroid-Refractory Microscopic Colitis (ACG 2026) - "Patients with histologically confirmed microscopic colitis and prior exposure to budesonide or prednisone were included. Advanced therapies assessed included anti-TNF agents (infliximab, adalimumab), anti-integrin therapy (vedolizumab), interleukin inhibitors (ustekinumab, risankizumab), JAK inhibitors (tofacitinib, upadacitinib), and immunomodulators (azathioprine, 6-mercaptopurine, methotrexate)... 34 patients were included in this analysis. Average bowel movements significantly decreased from 9.1 ± 4.4 to 2.2 ± 2.1 per day following AT, corresponding to a mean reduction of 6.9 ± 3.9, demonstrating a clinical response (p< 0.001). Most patients demonstrated symptomatic improvement or resolution of diarrhea and over 50% reported improvement in urgency and abdominal pain."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • CRP